These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 18697857)

  • 1. Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.
    Yoon H; Blaber SI; Evans DM; Trim J; Juliano MA; Scarisbrick IA; Blaber M
    Protein Sci; 2008 Nov; 17(11):1998-2007. PubMed ID: 18697857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases.
    Yoon H; Blaber SI; Li W; Scarisbrick IA; Blaber M
    Biol Chem; 2013 Jan; 394(1):137-47. PubMed ID: 23241590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation profiles and regulatory cascades of the human kallikrein-related peptidases.
    Yoon H; Laxmikanthan G; Lee J; Blaber SI; Rodriguez A; Kogot JM; Scarisbrick IA; Blaber M
    J Biol Chem; 2007 Nov; 282(44):31852-64. PubMed ID: 17823117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. Possible function in seminal plasma and skin.
    Emami N; Diamandis EP
    J Biol Chem; 2008 Feb; 283(6):3031-3041. PubMed ID: 18056261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional intersection of the kallikrein-related peptidases (KLKs) and thrombostasis axis.
    Blaber M; Yoon H; Juliano MA; Scarisbrick IA; Blaber SI
    Biol Chem; 2010 Apr; 391(4):311-20. PubMed ID: 20128685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interdependence of kallikrein-related peptidases in proteolytic networks.
    Beaufort N; Plaza K; Utzschneider D; Schwarz A; Burkhart JM; Creutzburg S; Debela M; Schmitt M; Ries C; Magdolen V
    Biol Chem; 2010 May; 391(5):581-7. PubMed ID: 20302517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
    Avgeris M; Scorilas A
    Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15.
    Yoon H; Blaber SI; Debela M; Goettig P; Scarisbrick IA; Blaber M
    Biol Chem; 2009 Apr; 390(4):373-7. PubMed ID: 19090718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the kallikrein-related peptidases for drug development.
    Sotiropoulou G; Pampalakis G
    Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of kallikrein-related peptidases in the skin - from physiology to diseases to therapeutic options.
    Fischer J; Meyer-Hoffert U
    Thromb Haemost; 2013 Sep; 110(3):442-9. PubMed ID: 23446429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation.
    Sotiropoulou G; Pampalakis G
    Biol Chem; 2010 Apr; 391(4):321-31. PubMed ID: 20180637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.
    Guillon-Munos A; Oikonomopoulou K; Michel N; Smith CR; Petit-Courty A; Canepa S; Reverdiau P; Heuzé-Vourc'h N; Diamandis EP; Courty Y
    J Biol Chem; 2011 Jul; 286(29):25505-18. PubMed ID: 21628462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation and activity of glycosylated KLKs 3, 4 and 11.
    Guo S; Briza P; Magdolen V; Brandstetter H; Goettig P
    Biol Chem; 2018 Sep; 399(9):1009-1022. PubMed ID: 29975661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kallikrein-related peptidases in lung diseases.
    Lenga Ma Bonda W; Iochmann S; Magnen M; Courty Y; Reverdiau P
    Biol Chem; 2018 Sep; 399(9):959-971. PubMed ID: 29604204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multiplatform Targeted Mass Spectrometry Assays.
    Karakosta TD; Soosaipillai A; Diamandis EP; Batruch I; Drabovich AP
    Mol Cell Proteomics; 2016 Sep; 15(9):2863-76. PubMed ID: 27371727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.
    Borgoño CA; Michael IP; Komatsu N; Jayakumar A; Kapadia R; Clayman GL; Sotiropoulou G; Diamandis EP
    J Biol Chem; 2007 Feb; 282(6):3640-52. PubMed ID: 17158887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional roles of human kallikrein-related peptidases.
    Sotiropoulou G; Pampalakis G; Diamandis EP
    J Biol Chem; 2009 Nov; 284(48):32989-94. PubMed ID: 19819870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6.
    Kantyka T; Fischer J; Wu Z; Declercq W; Reiss K; Schröder JM; Meyer-Hoffert U
    Peptides; 2011 Jun; 32(6):1187-92. PubMed ID: 21439340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
    Figueroa CD; Molina L; Bhoola KD; Ehrenfeld P
    Biol Chem; 2018 Sep; 399(9):937-957. PubMed ID: 29885274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolutionary history of tissue kallikreins.
    Pavlopoulou A; Pampalakis G; Michalopoulos I; Sotiropoulou G
    PLoS One; 2010 Nov; 5(11):e13781. PubMed ID: 21072173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.